Compounds > alendronate
Page last updated: 2024-10-22

alendronate and HIV Coinfection

alendronate has been researched along with HIV Coinfection in 15 studies

alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.

Research Excerpts

ExcerptRelevanceReference
"HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14)."9.11Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. ( Clotet, B; del Rio, L; Gel, S; Holgado, S; Martínez-López, E; Negredo, E; Paredes, R; Pérez-Alvarez, N; Rey-Joly, C; Rosales, J; Tena, X, 2005)
"Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection."9.11Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005)
"In this small study in children and adolescents perinatally infected with HIV with low LS BMD, 48 weeks of alendronate was well-tolerated, showed no safety concerns, and significantly improved LS and whole body BMD compared to participants on vitamin D/calcium supplementation and exercise alone."5.34Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age. ( Amaral, FR; Benson, J; Ferreira, F; Gaur, A; George, K; Gordon, C; Hazra, R; Jacobson, DL; Lindsey, JC; Pagano-Therrien, J; Siberry, GK; Spiegel, H, 2020)
"HIV-1-infected patients with osteoporosis were randomly assigned to alendronate 70 mg once-weekly plus dietary counselling (n = 11) or diet counselling alone (n = 14)."5.11Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. ( Clotet, B; del Rio, L; Gel, S; Holgado, S; Martínez-López, E; Negredo, E; Paredes, R; Pérez-Alvarez, N; Rey-Joly, C; Rosales, J; Tena, X, 2005)
"Alendronate, vitamin D, and calcium are safe and potentially useful in the treatment of osteopenia/osteoporosis associated with HIV infection."5.11Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. ( Claxton, SA; Hoffmann, ME; Mondy, K; Powderly, WG; Royal, M; Stoneman, JS; Tebas, P; Yarasheski, KH, 2005)
"Three completed randomised-controlled studies examined the role of alendronate in patients with HIV and osteopenia or osteoporosis."4.84Interventions for the treatment of decreased bone mineral density associated with HIV infection. ( Lin, D; Rieder, MJ, 2007)
"Alendronate was well tolerated, without significant adverse events."2.73Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. ( Alston-Smith, B; Benson, C; Gopalakrishnan, G; Hogg, E; Kendall, MA; McComsey, GA; Suckow, C; Swindells, S; Tebas, P; Wohl, DA, 2007)
"Osteoporosis is a growing concern among people living with HIV (PLWH) because of the recognized risk of fractures, which bring with them morbidity and mortality."2.53Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients. ( Negredo, E; Warriner, AH, 2016)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's8 (53.33)29.6817
2010's3 (20.00)24.3611
2020's4 (26.67)2.80

Authors

AuthorsStudies
Sanz, M1
Weideman, AMK1
Ward, AR1
Clohosey, ML1
Garcia-Recio, S1
Selitsky, SR1
Mann, BT1
Iannone, MA1
Whitworth, CP1
Chitrakar, A1
Garrido, C1
Kirchherr, J1
Coffey, AR1
Tsai, YH1
Samir, S1
Xu, Y1
Copertino, D1
Bosque, A1
Jones, BR1
Parker, JS1
Hudgens, MG1
Goonetilleke, N1
Soriano-Sarabia, N1
Kalayjian, RC1
McComsey, GA3
Jacobson, DL2
Lindsey, JC2
Gordon, C1
Hazra, R2
Spiegel, H1
Ferreira, F1
Amaral, FR1
Pagano-Therrien, J1
Gaur, A1
George, K1
Benson, J1
Siberry, GK2
Spiegel, HM1
Gordon, CM1
Natsag, J1
Kendall, MA2
Sellmeyer, DE1
Brown, TT1
Negredo, E3
Warriner, AH1
Paccou, J1
Viget, N1
Legrout-Gérot, I1
Yazdanpanah, Y1
Cortet, B1
Rebolledo, BJ1
Unnanuntana, A1
Lane, JM1
Martínez-López, E1
Paredes, R1
Rosales, J1
Pérez-Alvarez, N1
Holgado, S1
Gel, S1
del Rio, L1
Tena, X1
Rey-Joly, C1
Clotet, B2
Mondy, K1
Powderly, WG1
Claxton, SA1
Yarasheski, KH1
Royal, M1
Stoneman, JS1
Hoffmann, ME1
Tebas, P2
Martínez, E1
Cinquegrana, D1
Estany, C1
Lin, D1
Rieder, MJ1
Swindells, S1
Hogg, E1
Alston-Smith, B1
Suckow, C1
Gopalakrishnan, G1
Benson, C1
Wohl, DA1
Guaraldi, G1
Ventura, P1
Albuzza, M1
Orlando, G1
Bedini, A1
Esposito, R1

Clinical Trials (4)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Impact of Oral Alendronate Therapy on Bone Mineral Density in HIV-infected Children and Adolescents With Low Bone Mineral Density[NCT00921557]Phase 252 participants (Actual)Interventional2009-11-30Completed
The Prevalence of Vitamin D Deficiency and Effects of Vitamin D Supplementation in HIV-1 Infected Patients[NCT00306410]Phase 285 participants Interventional2006-01-31Recruiting
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Once-Weekly Alendronate in HIV-Infected Subjects With Decreased Bone Mineral Density Receiving Calcium and Vitamin D[NCT00061256]Phase 280 participants InterventionalCompleted
A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-naïve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy[NCT02322099]Phase 453 participants (Actual)Interventional2016-05-31Terminated (stopped due to Due to the COVID-19 pandemic the study was terminated prematurely)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change From Baseline to Week 96 in Lumbar Spine BMD

Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96

InterventionPercent change from baseline (Median)
1A: Alendronate/Alendronate24.9
1B: Alendronate/Placebo14.8

Percent Change From Baseline to Week 96 in Whole Body (With Head) BMD

Percent change was calculated as (measurement at week 96 - measurement at baseline)/measurement at baseline * 100%. Includes Groups 1A and 1B only. (NCT00921557)
Timeframe: Weeks 0 and 96

InterventionPercent change from baseline (Median)
1A: Alendronate/Alendronate19.6
1B: Alendronate/Placebo10.3

Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Lumbar Spine BMD

Percent change was calculated as (measurement at time T2 - measurement at time T1)/measurement at Time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144

InterventionPercent change (Median)
1B: Alendronate/Placebo (48 Week Change)0.9
2: Placebo/Alendronate (48 Week Change)2.0
1B: Alendronate/Placebo (96 Week Change)1.7

Percent Change From Week 48 to Week 96 (Group 1B), Week 48 to Week 144 (Group 1B), and Week 96 to 144 (Group 2) in Whole Body (With Head) BMD

Percent change was calculated as (measurement at time T2 - measurement at time T2)/measurement at time T1 * 100%. (NCT00921557)
Timeframe: Weeks 48, 96 and 144

InterventionPercent change (Median)
1B: Alendronate/Placebo (48 Week Change)0.8
2: Placebo/Alendronate (48 Week Change)0.5
1B: Alendronate/Placebo (96 Week Change)0.9

Percentage of Participants Developing New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures

Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Week 0 to 48

InterventionParticipants (Count of Participants)
1: Alendronate5
2: Placebo2

Change in CD4 Percent From Baseline

Change in percentage of lymphocytes that are CD4 cells calculated as measurement at each time point minus baseline measurement (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144

,,
Interventionpercent of lymphocytes that are CD4 cell (Median)
Week 48 - Week 0Week 96 - Week 0Week 144 - Week 0
1A: Alendronate/Alendronate001
1B: Alendronate/Placebo1-1-1
2: Placebo/Alendronate12-4

Change in Centers for Disease Control (CDC) HIV Disease Category

Percentage of participants advancing in CDC HIV disease category from baseline throughout study follow-up (NCT00921557)
Timeframe: Weeks 144

,,
InterventionParticipants (Count of Participants)
Week 0 to 48Week 48 to 96Week 96 to 144
1A: Alendronate/Alendronate100
1B: Alendronate/Placebo010
2: Placebo/Alendronate000

Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Lumbar Spine BMD

A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in lumbar spine BMD from baseline. Results represent average changes in lumbar spine BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

,
Interventionpercentage of baseline (Mean)
MaleFemaleNon-hispanicHispanic11 - < 15 years15 - < 19 years>= 19 yearsOn TenofovirNot on Tenofovir25-OH Vit D<30 ng/ml25-0H Vit D>=30 ng/mlBone age < 15 yearsBone age>=15 yearsTanner stage <= 3Tanner stage >= 4
1: Alendronate20.325.419.423.637.116.58.124.819.922.022.136.011.333.015.4
2: Placebo6.89.44.87.810.68.01.96.88.26.87.810.05.010.65.9

Effect of Other Known Bone Mineral Determinants (Age, Gender, Race/Ethnicity, Steroid Use, Depo-Provera, Tenofovir, Pubertal Stage, Bone Age, Vitamin D Status) and Inflammatory Cytokine Levels on Changes in Whole Body (With Head) BMD.

A slope was fit for each participant to their percent change [(measurement at time T - measurement at baseline)/measurement at baseline)*100%] in whole body (with head) BMD from baseline. Results represent average changes in whole body (with head) BMD over one year. Results are summarized for age, gender, ethnicity, tenofovir use, Tanner stage, bone age and vitamin D level. Only one participant was on steroids and none were using Dep-Provera. Inflammatory cytokine levels were not assayed. Results were combined for Groups 1A and 1B as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

,
Interventionpercentage of baseline (Mean)
MaleFemaleNon-HispanicHispanic11 - < 15 years15 - < 19 years>= 19 yearsOn tenofovirNot on tenofovir25-0H Vit D<30 ng/ml25-0H Vit D>=30 ng/mlBone age < 15 yearsBone age >=15 yearsTanner stage <= 3Tanner stage >= 4
1: Alendronate11.414.09.813.919.210.54.713.211.610.615.119.07.718.09.4
2: Placebo4.18.20.36.18.06.5-0.35.05.85.85.28.42.38.03.8

Percent Change From Baseline to Weeks 24 and 48 in Lumbar Spine BMD

Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

,
InterventionPercent change from baseline (Median)
Week 24Week 48
1: Alendronate14.415.9
2: Placebo5.57.1

Percent Change From Baseline to Weeks 24 and 48 in Whole Body (With Head) BMD

Percent change was calculated as (measurement at time T - measurement at baseline)/measurement at baseline * 100%. Results for Groups 1A and 1B were combined as both were on alendronate for the first 48 weeks. (NCT00921557)
Timeframe: Weeks 0, 24 and 48

,
InterventionPercent change from baseline (Median)
Week 24Week 48
1: Alendronate5.510.7
2: Placebo0.35.2

Percent of Participants With HIV-1 RNA <= 400 Copies/ml

Percent calculated as number of participants with HIV-1 RNA <= 400 copies/ml relative to the number of participants with HIV-1 RNA measured at that time point. (NCT00921557)
Timeframe: Weeks 0, 48, 96 and 144

,,
InterventionParticipants (Count of Participants)
Week 0Week 48Week 96Week 144
1A: Alendronate/Alendronate10101210
1B: Alendronate/Placebo16161210
2: Placebo/Alendronate15141310

Safety as Measured by the Incidence of New Signs, Symptoms, Hematology or Chemistry Laboratory Values Greater Than or Equal to Grade 3 or New Cases of Jaw Osteonecrosis, Atrial Fibrillation, or Non-healing Fractures

Signs, symptoms, and laboratory values were graded using the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0 (December 2004). (NCT00921557)
Timeframe: Weeks 0 to 144

,,
InterventionParticipants (Count of Participants)
Week 0 to 48Week 48 to 96Week 96 to 144
1A: Alendronate/Alendronate213
1B: Alendronate/Placebo334
2: Placebo/Alendronate223

Reviews

4 reviews available for alendronate and HIV Coinfection

ArticleYear
Pharmacologic approaches to the prevention and management of low bone mineral density in HIV-infected patients.
    Current opinion in HIV and AIDS, 2016, Volume: 11, Issue:3

    Topics: Alendronate; Anti-Inflammatory Agents; Bone Density; Bone Density Conservation Agents; Diphosphonate

2016
Bone loss in patients with HIV infection.
    Joint bone spine, 2009, Volume: 76, Issue:6

    Topics: Alendronate; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Bone Resorption

2009
Therapeutic management of bone demineralization in the HIV-infected population.
    AIDS (London, England), 2007, Mar-30, Volume: 21, Issue:6

    Topics: Alendronate; Anti-HIV Agents; Bone Density; Bone Density Conservation Agents; Calcium, Dietary; Diph

2007
Interventions for the treatment of decreased bone mineral density associated with HIV infection.
    The Cochrane database of systematic reviews, 2007, Apr-18, Issue:2

    Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium, Diet

2007

Trials

6 trials available for alendronate and HIV Coinfection

ArticleYear
Alendronate Improves Bone Mineral Density in Children and Adolescents Perinatally Infected With Human Immunodeficiency Virus With Low Bone Mineral Density for Age.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-22, Volume: 71, Issue:5

    Topics: Adolescent; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metab

2020
Safety and Efficacy of 48 and 96 Weeks of Alendronate in Children and Adolescents With Perinatal Human Immunodeficiency Virus Infection and Low Bone Mineral Density for Age.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021, 03-15, Volume: 72, Issue:6

    Topics: Adolescent; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; C

2021
Vitamin D, osteoprotegerin/receptor activator of nuclear factor-kappaB ligand (OPG/RANKL) and inflammation with alendronate treatment in HIV-infected patients with reduced bone mineral density.
    HIV medicine, 2016, Volume: 17, Issue:3

    Topics: Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Resorption; Cholecalciferol

2016
Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
    AIDS (London, England), 2005, Feb-18, Volume: 19, Issue:3

    Topics: Alendronate; Bone Density; Combined Modality Therapy; Follow-Up Studies; HIV Infections; HIV-1; Huma

2005
Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
    Journal of acquired immune deficiency syndromes (1999), 2005, Apr-01, Volume: 38, Issue:4

    Topics: Absorptiometry, Photon; Adult; Alendronate; Bone Density; Bone Diseases, Metabolic; Calcium; CD4 Lym

2005
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    AIDS (London, England), 2007, Nov-30, Volume: 21, Issue:18

    Topics: Absorptiometry, Photon; Alendronate; Biomarkers; Bone Density; Bone Density Conservation Agents; Cal

2007

Other Studies

5 other studies available for alendronate and HIV Coinfection

ArticleYear
Aminobisphosphonates reactivate the latent reservoir in people living with HIV-1.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Alendronate; HIV Infections; HIV Seropositivity; HIV-1; Humans; Virus Activation; Virus Latency

2023
Bisphosphonates in Perinatally Infected Children and Adolescents With Human Immunodeficiency Virus: Targeting Puberty.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2020, 08-22, Volume: 71, Issue:5

    Topics: Adolescent; Alendronate; Bone Density; Bone Diseases, Metabolic; Child; Diphosphonates; HIV; HIV Inf

2020
Bilateral pathologic hip fractures associated with antiretroviral therapy: a case report.
    The Journal of bone and joint surgery. American volume, 2011, Jul-20, Volume: 93, Issue:14

    Topics: Accidental Falls; Adenine; Alendronate; Anti-HIV Agents; Bone Density Conservation Agents; Comorbidi

2011
Alendronate treatment for osteoporosis in patients infected with human immunodeficiency virus.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2001, Aug-01, Volume: 33, Issue:3

    Topics: Alendronate; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Male; Middle Aged; Osteo

2001
Fosamax for HIV-related bone problems?
    TreatmentUpdate, 2001, Volume: 13, Issue:3

    Topics: Alendronate; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Osteoporosis

2001